ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. company was founded in 2003 and is based in New York, New York. ZIOPHARM Oncology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of proprietary small molecule drug candidates that are related to cancer therapeutics. Its primary product includes Palifosfamide (Zymafos or ZIO-201), which is in phase II randomized controlled trial for the treatment of metastatic or unresectable soft tissue sarcoma as front- or second-line therapy. The companys products in Phase I and/or II studies include Darinaparsin (Zinapar or ZIO-101), a novel anti-mitochondrial agent for the treatment of acute promyelocytic leukemia and for various other cancers; and Indibulin (Zybulin or ZIO-301), a novel small molecular-weight tubulin polymerization inhibitor. It has collaboration agreement with Harmon Hill, LLC to provide consulting and other services related to the company's development and commercialization of oncology therapeutics.

Contact Details

Office Address

ZIOPHARM Oncology, Inc.
1180 Avenue of the Americas, Suite 1920
New York, NY, USA 10036
Phone: (646) 214-0700
Fax: (646) 214-0711

Executives

Exec. Chairman and Chief Exec. Officer

Dr. Jonathan J. Lewis

Chief Operating Officer

Mr. Richard E. Bagley

Business Reviews for ZIOPHARM Oncology, Inc.

Related Companies

Zogenix, Inc.

Zogenix is intent on alleviating that nasty migraine of yours. The biopharmaceutical company is focused on developing and commercializing central nervous system (CNS) and therapeutic pain medications. The company received FDA approval for its Sumavel DosePro (sumatriptan) candidate in 2009. The drug, previously known as Intraject, utilizes the company's needle-free drug delivery technology and administers sumatriptan for the relief of acute migraines and cluster headaches. Its other late-stage candidate, ZX002, is an oral controlled release formulation of hydrocodone, used for the treatment of chronic pain. Biotechnology veteran Cam Garner founded Zogenix in 2006.

ZymoGenetics, Inc.

ZymoGenetics, Inc. company was founded in 1981 and is headquartered in Seattle, Washington. ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The company's product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein, which is in Phase Ib clinical trials for the treatment of viral infections and autoimmune diseases; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases. Its out-licensed product candidates include atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; Augment Bone Graft for orthopedic fracture and other bone defects; rFactor XIII for congenital factor XIII deficiency, cardiac surgery, and cancer related bleeding; Fibroblast growth factor-18 for osteoarthritis; IL-17 receptor C for inflammatory diseases; and IL-20 and IL-22 receptor subunit alpha for psoriasis. The company also offers out-licensed commercial products comprising Novolin and insulin analogs for diabetes; NovoSeven for the treatment of hemophilia; Regranex for wound healing; GEM 21S for periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor for treatment of myocardial infarction. ZymoGenetics has collaboration agreements with Bayer Schering Pharma AG; Bristol-Myers Squibb Company; and Merck Serono S.A.